The development of biomaterials for use in tissue engineering processes has not so far followed a scientifically valid pathway; there have been no properly constituted specifications for these biomaterials, whose choice has often been dictated by the perceived need to comply with prior FDA approval for use of the materials in nontissue engineering applications. This short essay discusses the difficulties that have resulted in this approach and provides both conceptual and practical solutions for the future, based on sound principles of biocompatibility and the need to use tissue engineering templates that replicate the niche of the target cells.